Roger Song
Stock Analyst at Jefferies
(4.31)
# 368
Out of 5,182 analysts
55
Total ratings
47.92%
Success rate
23.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTMX CytomX Therapeutics | Maintains: Buy | $8 → $16 | $4.24 | +277.36% | 4 | Mar 18, 2026 | |
| MANE Veradermics | Initiates: Buy | $75 | $59.98 | +25.04% | 1 | Mar 2, 2026 | |
| BIOA BioAge Labs | Upgrades: Buy | $9 → $62 | $17.79 | +248.51% | 3 | Feb 18, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $310 → $371 | $258.33 | +43.61% | 2 | Feb 17, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $95 → $118 | $104.09 | +13.37% | 1 | Feb 2, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $13 → $42 | $15.67 | +168.03% | 3 | Jan 22, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $99 → $121 | $77.85 | +55.43% | 12 | Nov 26, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $45 | $63.60 | -29.25% | 1 | Nov 13, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $7.24 | +120.99% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $574.77 | -1.87% | 1 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.85 | +170.27% | 1 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $17 | $0.75 | +2,166.67% | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $36 | $32.86 | +9.56% | 1 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $54 | $47.33 | +14.09% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $6 | $5.91 | +1.52% | 2 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.41 | +325.53% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.12 | +124.36% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $7.16 | +263.13% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $8.85 | +216.38% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $4.08 | +71.57% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $67.30 | +32.24% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $8.54 | +192.74% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $16.24 | +152.46% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $21.28 | +64.47% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $61.69 | +109.11% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $104.59 | -7.26% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $34.95 | +214.74% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $3.38 | +935.50% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.40 | +104.55% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $210 | $26.76 | +684.75% | 1 | Sep 2, 2020 |
CytomX Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $8 → $16
Current: $4.24
Upside: +277.36%
Veradermics
Mar 2, 2026
Initiates: Buy
Price Target: $75
Current: $59.98
Upside: +25.04%
BioAge Labs
Feb 18, 2026
Upgrades: Buy
Price Target: $9 → $62
Current: $17.79
Upside: +248.51%
Krystal Biotech
Feb 17, 2026
Maintains: Buy
Price Target: $310 → $371
Current: $258.33
Upside: +43.61%
Protagonist Therapeutics
Feb 2, 2026
Maintains: Buy
Price Target: $95 → $118
Current: $104.09
Upside: +13.37%
Corvus Pharmaceuticals
Jan 22, 2026
Maintains: Buy
Price Target: $13 → $42
Current: $15.67
Upside: +168.03%
Nektar Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $99 → $121
Current: $77.85
Upside: +55.43%
Oruka Therapeutics
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $63.60
Upside: -29.25%
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $7.24
Upside: +120.99%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $574.77
Upside: -1.87%
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.85
Upside: +170.27%
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.75
Upside: +2,166.67%
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $32.86
Upside: +9.56%
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $47.33
Upside: +14.09%
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $5.91
Upside: +1.52%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.41
Upside: +325.53%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $3.12
Upside: +124.36%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $7.16
Upside: +263.13%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $8.85
Upside: +216.38%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $4.08
Upside: +71.57%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $67.30
Upside: +32.24%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $8.54
Upside: +192.74%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $16.24
Upside: +152.46%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $21.28
Upside: +64.47%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $61.69
Upside: +109.11%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $104.59
Upside: -7.26%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $34.95
Upside: +214.74%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $3.38
Upside: +935.50%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $4.40
Upside: +104.55%
Sep 2, 2020
Initiates: Buy
Price Target: $210
Current: $26.76
Upside: +684.75%